DSM Capital Partners LLC Invests $47,000 in Novo Nordisk A/S (NYSE:NVO)

DSM Capital Partners LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 452 shares of the company’s stock, valued at approximately $47,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pacific Center for Financial Services boosted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Bell Investment Advisors Inc boosted its position in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth $26,000. Tyler Stone Wealth Management boosted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. boosted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NVO. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Up 0.3 %

Shares of Novo Nordisk A/S stock traded up $0.47 during trading on Friday, reaching $136.04. The stock had a trading volume of 2,845,222 shares, compared to its average volume of 4,075,833. The company has a market capitalization of $610.48 billion, a price-to-earnings ratio of 46.91, a P/E/G ratio of 1.40 and a beta of 0.43. The stock has a fifty day moving average price of $128.21 and a two-hundred day moving average price of $116.55. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Sell-side analysts predict that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.